Trump touts 400–600% drug cuts
- Donald Trump’s drug-pricing push resurfaced after critics mocked his talk of “400–600%” cuts, while the actual White House policy promises U.S. prices match lower foreign ones. - The real numbers tied to Trump’s May 12, 2025 order were 30% to 80%, later 50% to 90% in remarks — not reductions beyond 100%. - It matters because the administration is still building a most-favored-nation system, but experts say the path from slogan to pharmacy savings remains murky.
Prescription drugs are the kind of issue where everybody agrees the prices are brutal, but the math still matters. That is why the “400–600%” line blew up. A price cannot fall by more than 100% without turning negative, so the claim landed less like a policy promise and more like a category error. The real policy underneath the noise is Trump’s revived “most-favored-nation” drug pricing push — a plan to tie some U.S. drug prices to the lowest prices paid in other wealthy countries. ### What did Trump actually say? The cleanest paper trail is not 400–600%. On May 12, 2025, Trump signed an executive order on most-favored-nation pricing and said some prescription drug prices could fall “almost immediately” by 50% to 80% to 90%. In a social post the same day, he also used “59%, PLUS!” The White House order itself does not promise a fixed across-the-board cut. It sets a policy goal — Americans should get the lowest price available in comparable developed countries. (whitehouse.gov) ### So where does the 400–600% problem come from? Basically, it is arithmetic. If a drug costs $100 and drops 50%, it goes to $50. If it drops 80%, it goes to $20. But a 400% cut would imply the price falls past zero. That is why critics treated the line as obviously wrong on its face. Trump has also argued that Americans sometimes pay five, six, seven, or even 10 times what other countries pay. That kind of ratio can get mangled into a bogus “percent cut” if somebody talks too loosely. (whitehouse.gov) ### What is the policy actually trying to do? The idea is simple enough. The administration wants drugmakers to offer Americans the same low prices they offer abroad — the “most favored nation” price. The May 12, 2025 executive order told federal agencies to push that framework, and later administration material said the effort would reach across private insurance, Medicaid, and direct-to-consumer channels like TrumpRx.gov. A May 2026 White House presentation said the administration had reached voluntary agreements with 17 large manufacturers and projected $529 billion in 10-year savings from future launches, plus $64.3 billion from Medicaid savings on existing drugs. (factcheck.org) ### Why do people think the idea could help? Because U.S. drug prices really are unusually high. The order says Americans often pay almost three times more for the same medicines. Independent fact-checking landed in a similar zone, citing RAND work showing U.S. prices averaged 2.78 times those in 33 other developed countries, and brand-name drugs were 4.22 times pricier before manufacturer discounts. So the gap is real — just not a license to say any percentage you want. (whitehouse.gov) ### Then what’s the catch? The catch is implementation. The executive order was broad, but light on the mechanics. It did not spell out exactly which drugs would be covered at the start, how foreign reference prices would be calculated, or how quickly private-market prices could actually move. Analysts and policy experts have been saying the same thing since the order came out — lower prices are conceivable in theory, but the legal and logistical path is messy. (whitehouse.gov) ### Why is Sanders jumping on it? Because this is a perfect political target. Sanders has spent years attacking high drug prices, so a mathematically impossible boast lets him hit both Big Pharma and Trump-style hype at once. The broader argument is not really about whether drugs are too expensive — most people agree they are. It is about whether a headline-grabbing number means anything before patients actually see smaller bills at the pharmacy. That part is still unresolved. (factcheck.org) ### Bottom line? The story is not that Trump discovered a way to cut drug prices by 400–600%. The story is that his administration is still pursuing a real most-favored-nation pricing campaign, while the loudest number attached to it is the easiest part to debunk. If this policy succeeds, the proof will be boring — lower receipts, narrower price gaps, and rules that survive court fights. Until then, the math is the first fact-check. (whitehouse.gov) (factcheck.org)